This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oxygen Biotherapeutics Reports Financial Results For Fiscal Year 2013

Oxygen Biotherapeutics, Inc., (“OBI”) (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, today announced results for the fiscal year (FY) ended April 30, 2013.

Financial Highlights:
  • Government grant revenue increased 263% year-over-year to $1.14 million due to progress of the underlying studies for FDA-required preclinical trials on Oxycyte® and the achievement of contractual milestones under the grant
  • Raised approximately $2.1 million in an offering of Series B preferred stock and warrants
  • Reduced operating expenses by 26% year-over-year as a result of focusing operations on Oxycyte® as a therapeutic for critical indications including TBI
  • Net operating loss narrowed by 37% and net loss attributable to common shareholder narrowed by 34% driven by increased revenues and reduced operating expenses
  • Out-licensed Dermaycte® product line in February 2013 to Valor SA of Switzerland in exchange for non–refundable annual licensing fees and royalty revenues

Clinical Highlights:
  • Made significant advancements in preclinical trials requested by the FDA to test the safety profile of Oxycyte® for the treatment of traumatic brain injury (TBI), with preclinicals scheduled for completion in the second quarter of fiscal year 2014
  • Secured exclusive long-term supply of cGMP-compliant Oxycyte® for ongoing clinical trials
  • Signed research agreement for the U.S. Navy to fund a study of Oxycyte® as potential treatment for hemorrhagic shock
  • Secured additional research agreement for the U.S. Navy to fund a study of Oxycyte® as an intravenous treatment for infected wounds and related injuries
  • Aurum Biosciences, the Company’s research partner for stroke indications, and the University of Glasgow, demonstrated in a study, the ability of Oxycyte® to supply oxygen to critical penumbral tissue in acute ischemic stroke

“In fiscal 2013 we successfully executed on focusing the Company’s operations on Oxycyte® for critical indications including TBI and stroke. During the 2013 fiscal year we conducted several FDA requested preclinical trials on Oxycyte® designed to address the FDA’s clinical hold on PFC emulsions,” stated Michael Jebsen, Interim CEO, President and Chief Financial Officer. “We also continue progress with our Phase IIb trials for Oxycyte® in the treatment of TBI in Switzerland and Israel. We further streamlined and reduced our operating expenses and have out-licensed our cosmetics line with the goal of creating high-margin licensing revenues. We seek additional out-licensing opportunities for a broad range of non-core indications of our platform oxygen-carrying technology.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs